GlassScriptPhysician profile
Amirali Popatia
NPI 1952349920
$18,139.85
in general payments reported to CMS, 2019-2025
64 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,367 · 2020: $2,247 · 2021: $2,522 · 2022: $2,453 · 2023: $2,600 · 2024: $1,964 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,450 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,450.37 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,726.99 | 2019-2025 | Venclexta, Tecentriq, Alecensa |
| Merck Sharp & Dohme LLC | $2,100.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $1,275.86 | 2019-2023 | Vectibix, Xgeva, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $1,208.51 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $1,069.63 | 2019-2025 | Enhertu, Tagrisso |
| Lilly USA, LLC | $820.23 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $692.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $675.95 | 2020-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $495.79 | 2021-2025 | Fotivda |
| Spectrum Pharmaceuticals INC. | $431.22 | 2023-2025 | Rolvedon |
| Seagen INC. | $403.45 | 2019-2023 | Padcev |
| Pfizer INC. | $397.21 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $366.78 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Glaxosmithkline, LLC. | $349.51 | 2020-2022 | |
| Puma Biotechnology, INC. | $348.70 | 2021-2025 | Nerlynx |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amirali Popatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.